MNK Stock Price, News & Analysis

Mallinckrodt (MNK) reported Q2 2025 financial results and provided guidance following its merger with Endo. Legacy Mallinckrodt achieved net sales of $485.1M (down 5.7% YoY, but up 8.5% excluding Therakos divestiture) and net income of $2.4M. Legacy Endo reported flat revenues of $447.8M with a net loss of $59.6M.

Key highlights include Acthar Gel's highest growth in over a decade (up 48.8% to $175.1M) and XIAFLEX's 9.4% growth to $138.6M. The combined company projects 2025 net sales of $3.57B-$3.62B and adjusted EBITDA of $1.10B-$1.13B. The planned spin-off of Par Health remains on track for Q4 2025, with expected net sales of $1.72B-$1.75B.

The company raised Acthar Gel's 2025 growth guidance to 20-30% from high-single digits and reaffirmed XIAFLEX's high-single digit growth outlook.

Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.

The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.

Mallinckrodt (NYSE:MNK) and Endo have completed their merger to create a global therapeutics leader. Under the deal terms, Endo shareholders received $100 million in cash and will own 49.9% of Mallinckrodt, while pre-transaction Mallinckrodt shareholders retain 50.1% ownership.

The merger includes plans to spin off their combined generics and sterile injectables business (Par Health) as an independent company by Q4 2025. The company expects to achieve $150 million in annual pre-tax synergies by Year 3, with $75 million in the first year. A $1.35 billion secured credit facility was established to refinance debt and fund the transaction.

Post spin-off, the branded therapeutics company will seek NYSE listing. Siggi Olafsson continues as CEO, with Paul Efron serving as Board Chair of the combined entity.

Mallinckrodt (NYSE:MNK), a global specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025. The company will host an investor conference call at 8:30 a.m. ET.

Investors can participate through multiple channels, including a live dial-in registration system and an audio-only webcast. The presentation will also be accessible through Mallinckrodt's Investor Relations website.

Mallinckrodt announced survey results regarding patient experience with their Acthar Gel Single-Dose Pre-filled SelfJect Injector. The study, published in Advances in Therapy, revealed high patient satisfaction with the device's ease of use, convenience, and confidence in administration. The SelfJect injector, FDA-approved for treating various chronic and acute inflammatory conditions, is available in 40 USP units/0.5 mL and 80 USP units/1.0 mL doses for adult use. The device has received recognition from the Arthritis Foundation, highlighting its importance for patients with dexterity and visual challenges. The survey provides valuable real-world insights into patient experiences with the delivery system beyond clinical trials.

Mallinckrodt and Endo announced their planned leadership structure following their upcoming merger, scheduled for completion in H2 2025. The merged entity will create two distinct companies: a branded specialty pharmaceuticals company and Par Health, a spin-off focusing on generics and sterile injectables (GxSI). Siggi Olafsson, current Mallinckrodt CEO, will lead the merged company. The leadership team combines executives from both companies, including Tracy Basso (CHRO), Mark Bradley (Chief Integration Officer), Lisa French (CCO), and others. Stephen Welch, currently Head of Specialty Generics at Mallinckrodt, will become CEO of Par Health post-spin-off. The company is actively recruiting for key positions including CFO, Business Development & Strategy, and R&D leadership. The merger remains subject to shareholder approval and customary closing conditions.

Mallinckrodt presented data from a real-world chart review of Acthar® Gel in treating systemic lupus erythematosus (SLE) at LUPUS 2025. The study analyzed 56 patients treated with Acthar Gel between April 2022 and November 2024. Key findings showed that 89% of patients experienced improved health status after treatment, with 82% reporting overall symptom improvements. The patient population was predominantly female (84%) and 50% African-American. Notable improvements were observed in pain (54%), fatigue (44%), and physical function (38%). The average treatment duration was 8 months, with 91% of patients receiving 40-80 units twice weekly. Additionally, 44% of patients reported reduced corticosteroid use. However, the study had limitations including small sample size and potential methodology variables.

Mallinckrodt (MNK) and Endo (OTCQX: NDOI) have made significant progress towards their proposed merger announced in March 2025. Key developments include: S-4 registration statement becoming effective, expiration of HSR waiting period, and Irish High Court approval for shareholder meetings. Both companies have scheduled shareholder votes for June 13, 2025.

The merger plan includes spinning off the combined generic pharmaceuticals and Endo's sterile injectables business into a separate entity from the branded pharmaceuticals business. Post-merger, Mallinckrodt shareholders will own 50.1% of the combined company, while Endo shareholders will receive $80 million in cash and own 49.9%. The deal is expected to close in H2 2025, with Dublin, Ireland serving as global headquarters.

Mallinckrodt (MNK) reported Q1 2025 financial results with net sales of $419.9 million, showing a 10% year-over-year decrease, though excluding Therakos divestiture, sales grew 2.5%. The company posted a net loss of $27.7 million and Adjusted EBITDA of $102.3 million. Key highlights include:

Acthar Gel sales increased 12.3% to $115.4 million, marking its fifth consecutive quarter of growth. The SelfJect device now accounts for >70% of new prescriptions. INOmax EVOLVE DS delivery system is now in over 50 hospitals with 400+ systems placed.

The company's cash balance stood at $422.2 million, with total debt reduced by 47.5% YoY to $864.6 million. Mallinckrodt reaffirmed its 2025 guidance with expected net sales of $1.7-1.8 billion and Adjusted EBITDA of $480-520 million. The company is progressing toward completing its merger with Endo in H2 2025.